Oncotarget

Reviews:

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

Fanny Le Du _, Bedrich L. Eckhardt, Bora Lim, Jennifer K. Litton, Stacy Moulder, Funda Meric-Bernstam, Ana M. Gonzalez-Angulo and Naoto T. Ueno

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:12890-12908. https://doi.org/10.18632/oncotarget.3849

Metrics: PDF 4175 views  |   HTML 3173 views  |   ?  


Abstract

Fanny Le Du1,2, Bedrich L. Eckhardt1, Bora Lim1,6, Jennifer K. Litton1,3,6, Stacy Moulder1,6, Funda Meric-Bernstam4,6, Ana M. Gonzalez-Angulo1,5,6, Naoto T. Ueno1,6

1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2Department of Medical Oncology, Eugène Marquis Cancer Center, Rennes, France

3Clinical Cancer Genetics Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA

4Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

6The University of Texas MD Anderson Women’s Cancer Moons Shot Program, Houston, TX, USA

Correspondence to:

Naoto T. Ueno, e-mail: nueno@mdanderson.org

Keywords: triple-negative breast cancer, gene expression profiling, epithelial-mesenchymal transition, immunotherapy, targeted therapy

Received: February 17, 2015     Accepted: April 24, 2015     Published: May 07, 2015

ABSTRACT

Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC). We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development. With the ultimate aim to streamline translational medicine, we linked these categories of TNBC according to their gene-expression signatures, biological function, and clinical outcome. To this end, we define five potential clinically actionable groupings of TNBC: 1) basal-like TNBC with DNA-repair deficiency or growth factor pathways; 2) mesenchymal-like TNBC with epithelial-to-mesenchymal transition and cancer stem cell features; 3) immune-associated TNBC; 4) luminal/apocrine TNBC with androgen-receptor overexpression; and 5) HER2-enriched TNBC. For each defined subtype, we highlight the major biological pathways and discuss potential targeted therapies in TNBC that might abrogate disease progression. However, many of these potential targets need clinical validation by clinical trials. We have yet to know how we can enrich the targets by molecular classifications.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3849